Methylation and Mutations in Lung Tumors of Smokers and Non-Smokers
Author Information
Author(s): Liu Yang, Gao Weimin, Siegfried Jill M, Weissfeld Joel L, Luketich James D, Keohavong Phouthone
Primary Institution: University of Pittsburgh
Hypothesis
The study investigates the differences in promoter methylation and mutations in lung tumors between smokers and never-smokers.
Conclusion
RASSF1A and DAPK gene promoter methylation is common in lung tumors, but not linked to smoking status or mutations in K-ras, p53, or EGFR.
Supporting Evidence
- RASSF1A promoter methylation was found in 46.7% of patients.
- DAPK promoter methylation frequency was 32.8%.
- Methylation did not differ significantly between smokers and never-smokers.
- RASSF1A methylation was significantly associated with adenocarcinoma.
Takeaway
The study found that certain changes in lung tumors happen often, but they don't depend on whether the person smoked or not.
Methodology
Promoter methylation was analyzed using a modified two-stage methylation-specific PCR.
Limitations
The study only included Caucasian patients from a specific region, which may limit generalizability.
Participant Demographics
122 lung cancer patients, including 81 smokers and 41 never-smokers, predominantly Caucasian.
Statistical Information
P-Value
p = 0.031 for RASSF1A and p = 0.063 for DAPK
Confidence Interval
95% CI = 0.454–0.962 for RASSF1A
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website